CY1106462T1 - Συστηματα απελευθερωσης φαρμακου με βαση λιπιδιο για τοπικη εφαρμογη - Google Patents
Συστηματα απελευθερωσης φαρμακου με βαση λιπιδιο για τοπικη εφαρμογηInfo
- Publication number
- CY1106462T1 CY1106462T1 CY20071100522T CY071100522T CY1106462T1 CY 1106462 T1 CY1106462 T1 CY 1106462T1 CY 20071100522 T CY20071100522 T CY 20071100522T CY 071100522 T CY071100522 T CY 071100522T CY 1106462 T1 CY1106462 T1 CY 1106462T1
- Authority
- CY
- Cyprus
- Prior art keywords
- drug release
- topical application
- release systems
- based drug
- lipid based
- Prior art date
Links
- 150000002632 lipids Chemical class 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 230000000699 topical effect Effects 0.000 title 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 abstract 2
- 102000015439 Phospholipases Human genes 0.000 abstract 2
- 108010064785 Phospholipases Proteins 0.000 abstract 2
- 102100026918 Phospholipase A2 Human genes 0.000 abstract 1
- 101710096328 Phospholipase A2 Proteins 0.000 abstract 1
- 230000000711 cancerogenic effect Effects 0.000 abstract 1
- 231100000315 carcinogenic Toxicity 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 229940039227 diagnostic agent Drugs 0.000 abstract 1
- 239000000032 diagnostic agent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Cosmetics (AREA)
Abstract
Η εφεύρεση σχετίζεται με την στόχευση των διαγνωστικών παραγόντων με την χρήση συνθέσεων που βασίζονται στα λιπίδια. Η εφεύρεση είναι χρήσιμη στη διάγνωση διαφόρων ασθενειών που σχετίζονται ή προκύπτουν από αυξημένα επίπεδα της δραστικότητας της έξω-κυτταρικής φωσφολιπάσης (phospholipase) PLA2 στον ασθενή ιστό κ.λ.π. σε καρκινογόνες, μολυσματικές και φλεγμονώδεις συνθήκες.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200000616 | 2000-04-12 | ||
PCT/DK2001/000267 WO2001076555A2 (en) | 2000-04-12 | 2001-04-11 | Lipid-based drug delivery systems for topical application |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1106462T1 true CY1106462T1 (el) | 2012-01-25 |
Family
ID=8159422
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20061101675T CY1105792T1 (el) | 2000-04-12 | 2006-11-16 | Συστηματα με βαση λιπιδια για την στοχευση με διαγνωστικους παραγοντες |
CY20071100522T CY1106462T1 (el) | 2000-04-12 | 2007-04-16 | Συστηματα απελευθερωσης φαρμακου με βαση λιπιδιο για τοπικη εφαρμογη |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20061101675T CY1105792T1 (el) | 2000-04-12 | 2006-11-16 | Συστηματα με βαση λιπιδια για την στοχευση με διαγνωστικους παραγοντες |
Country Status (11)
Country | Link |
---|---|
US (4) | US20030170297A1 (el) |
EP (3) | EP1272225B1 (el) |
JP (3) | JP2003530338A (el) |
AT (2) | ATE336267T1 (el) |
AU (3) | AU2001248303A1 (el) |
CY (2) | CY1105792T1 (el) |
DE (3) | DE60122304T2 (el) |
DK (3) | DK1272225T3 (el) |
ES (3) | ES2280355T3 (el) |
PT (3) | PT1272161E (el) |
WO (3) | WO2001076556A2 (el) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020001614A1 (en) * | 2000-02-10 | 2002-01-03 | Kent Jorgensen | Lipid-based drug delivery systems containing phospholipase A2 degradable lipid derivatives and the therapeutic uses thereof |
WO2002085391A1 (es) * | 2001-04-24 | 2002-10-31 | Luis Alberto Costa | Uso de una fosfolipasa a2 para la preparacion de composiciones farmaceuticas y/o cosmeticas para la prevencion y/o el tratamiento local y/o sistemico de enfermedades y/o procesos provocados por patogenos intra y extracelulares que expresen fosfolipidos de membrana |
US20050123925A1 (en) * | 2002-11-15 | 2005-06-09 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US20050112065A1 (en) * | 2003-07-09 | 2005-05-26 | Drummond Daryl C. | Remote detection of substance delivery to cells |
US20050266066A1 (en) * | 2003-10-20 | 2005-12-01 | Nof Corporation | Phospholipid membrane preparation |
WO2005077963A1 (fr) * | 2004-01-16 | 2005-08-25 | Institut Superieur Agricole De Beauvais | DErivEs de saccharides et d'itols possEdant un groupement O-alkyle ou un groupement O-alkyle et un groupement O-n-butanoyle. Applications comme mEdicaments dans les pathologies prolifEratives tumorales ou bEnignes. |
US20080113014A1 (en) * | 2004-01-28 | 2008-05-15 | Ltt Bio-Pharma Co., Ltd. | Method for Screening for Compounds Safe for Gastric Mucosa |
DE102004010387A1 (de) * | 2004-03-03 | 2005-09-22 | Siemens Ag | Kontrastmittel für die Röntgen-Computertomographie |
WO2006086992A2 (en) * | 2005-02-18 | 2006-08-24 | Liplasome Pharma A/S | Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands |
JP2006248978A (ja) | 2005-03-10 | 2006-09-21 | Mebiopharm Co Ltd | 新規なリポソーム製剤 |
US20090110633A1 (en) * | 2005-03-14 | 2009-04-30 | Shiladitya Sengupta | Nanocells for Diagnosis and Treatment of Diseases and Disorders |
PL1933809T3 (pl) * | 2005-10-11 | 2012-09-28 | Yissum Research Development Company Of The Hebrew Univ Of Jerusalem | Kompozycje do dostarczania donosowego |
WO2007071402A1 (en) * | 2005-12-23 | 2007-06-28 | Jado Technologies Gmbh | Means and methods for the treatment and prevention of allergic diseases |
JP2011026294A (ja) * | 2009-06-26 | 2011-02-10 | Canon Inc | 化合物 |
US8993715B2 (en) * | 2009-07-06 | 2015-03-31 | Canon Kabushiki Kaisha | Labeled protein and method for obtaining the same |
DE112010003355T5 (de) | 2009-08-21 | 2012-07-12 | Targeted Delivery Technologies Ltd. | Veskuläre Formulierungen |
DK177532B1 (en) | 2009-09-17 | 2013-09-08 | Bio Bedst Aps | Medical use of sPLA2 hydrolysable liposomes |
DK177529B1 (en) * | 2009-10-23 | 2013-09-08 | Bio Bedst Aps | Liposomes with improved storage stability |
WO2011102905A1 (en) * | 2010-02-19 | 2011-08-25 | Robert Shorr | Imageable lipid-oil-water nanoemulsion diagnostic delivery system |
WO2011102906A1 (en) * | 2010-02-19 | 2011-08-25 | Robert Shorr | Imageable lipid-oil-water nanoemulsion delivery system |
WO2011102904A1 (en) * | 2010-02-19 | 2011-08-25 | Robert Shorr | Imageable lipid-oil-water nanoemulsion therapeutic delivery system |
JP2015509507A (ja) * | 2012-03-09 | 2015-03-30 | ウニベルシダーヂ フェデラル ヂ ミナス ジェライス−ウエフィエミジェー | 内臓リーシュマニア症を治療するための従来型リポソームと長期循環型リポソームを含有する医薬組成物 |
GB201205642D0 (en) | 2012-03-29 | 2012-05-16 | Sequessome Technology Holdings Ltd | Vesicular formulations |
WO2014047116A1 (en) * | 2012-09-18 | 2014-03-27 | Comfort Care For Animals Llc | Encapsulating liposomes |
LT3316856T (lt) | 2015-06-30 | 2021-07-12 | Sequessome Technology Holdings Limited | Mišrios kompozicijos |
WO2018087720A1 (en) | 2016-11-14 | 2018-05-17 | Novartis Ag | Compositions, methods, and therapeutic uses related to fusogenic protein minion |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0714865B2 (ja) * | 1986-10-28 | 1995-02-22 | 武田薬品工業株式会社 | リポソ−ム製剤およびその製造法 |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5925375A (en) * | 1987-05-22 | 1999-07-20 | The Liposome Company, Inc. | Therapeutic use of multilamellar liposomal prostaglandin formulations |
FR2638639A1 (fr) * | 1988-11-08 | 1990-05-11 | Parincos Parfumerie Cosmet Int | Composition et procede d'obtention de liposomes oligolamellaires en vue d'une application en cosmetologie et dermatologie topique |
US5153000A (en) * | 1988-11-22 | 1992-10-06 | Kao Corporation | Phosphate, liposome comprising the phosphate as membrane constituent, and cosmetic and liposome preparation comprising the liposome |
US4874794A (en) * | 1989-04-28 | 1989-10-17 | Lidak Biopharmaceuticals | Inflammatory disease treatment |
JPH0370491A (ja) | 1989-08-04 | 1991-03-26 | Toshiba Corp | 電動機制御装置 |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5705187A (en) * | 1989-12-22 | 1998-01-06 | Imarx Pharmaceutical Corp. | Compositions of lipids and stabilizing materials |
US5580575A (en) * | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
US6165500A (en) * | 1990-08-24 | 2000-12-26 | Idea Ag | Preparation for the application of agents in mini-droplets |
CA2067754C (en) * | 1990-08-24 | 2002-06-04 | Gregor Cevc | Preparation for the application of agents in mini-droplets |
US5723115A (en) * | 1991-05-02 | 1998-03-03 | W. Alton Jones Cell Science Center, Inc. | Inhibition of adipose tissue development and obesity |
US5484911A (en) * | 1993-04-01 | 1996-01-16 | Health Research, Inc. | Nucleoside 5'-diphosphate conjugates of ether lipids |
DE4408011C1 (de) * | 1994-03-10 | 1995-11-02 | Max Delbrueck Centrum | Pharmazeutisches Mittel zur Tumortherapie |
US20020048596A1 (en) * | 1994-12-30 | 2002-04-25 | Gregor Cevc | Preparation for the transport of an active substance across barriers |
US5942246A (en) * | 1996-02-16 | 1999-08-24 | The Liposome Company, Inc. | Etherlipid containing multiple lipid liposomes |
US5827836A (en) | 1996-11-15 | 1998-10-27 | Clarion Pharmaceuticals Inc. | Retinoid glycerol phospholipid conjugates |
US6120751A (en) * | 1997-03-21 | 2000-09-19 | Imarx Pharmaceutical Corp. | Charged lipids and uses for the same |
US6048736A (en) * | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
US6444640B1 (en) * | 1999-09-30 | 2002-09-03 | Ludwig Institute For Cancer Research | Compositions of trail and DNA damaging drugs and uses thereof |
-
2001
- 2001-04-11 EP EP01921263A patent/EP1272225B1/en not_active Expired - Lifetime
- 2001-04-11 PT PT01921262T patent/PT1272161E/pt unknown
- 2001-04-11 AU AU2001248303A patent/AU2001248303A1/en not_active Abandoned
- 2001-04-11 JP JP2001574073A patent/JP2003530338A/ja not_active Withdrawn
- 2001-04-11 ES ES01921261T patent/ES2280355T3/es not_active Expired - Lifetime
- 2001-04-11 DE DE60122304T patent/DE60122304T2/de not_active Expired - Fee Related
- 2001-04-11 DE DE60126072T patent/DE60126072T2/de not_active Expired - Fee Related
- 2001-04-11 WO PCT/DK2001/000268 patent/WO2001076556A2/en active IP Right Grant
- 2001-04-11 ES ES01921263T patent/ES2270991T3/es not_active Expired - Lifetime
- 2001-04-11 DK DK01921263T patent/DK1272225T3/da active
- 2001-04-11 ES ES01921262T patent/ES2295149T3/es not_active Expired - Lifetime
- 2001-04-11 US US10/239,514 patent/US20030170297A1/en not_active Abandoned
- 2001-04-11 WO PCT/DK2001/000269 patent/WO2001076644A2/en active IP Right Grant
- 2001-04-11 AT AT01921263T patent/ATE336267T1/de not_active IP Right Cessation
- 2001-04-11 AT AT01921262T patent/ATE382333T1/de not_active IP Right Cessation
- 2001-04-11 EP EP01921262A patent/EP1272161B1/en not_active Expired - Lifetime
- 2001-04-11 AU AU2001248302A patent/AU2001248302A1/en not_active Abandoned
- 2001-04-11 DK DK01921261T patent/DK1272160T3/da active
- 2001-04-11 PT PT01921263T patent/PT1272225E/pt unknown
- 2001-04-11 EP EP01921261A patent/EP1272160B1/en not_active Expired - Lifetime
- 2001-04-11 JP JP2001574074A patent/JP2003530339A/ja not_active Withdrawn
- 2001-04-11 AU AU2001248301A patent/AU2001248301A1/en not_active Abandoned
- 2001-04-11 PT PT01921261T patent/PT1272160E/pt unknown
- 2001-04-11 DE DE60132184T patent/DE60132184T2/de not_active Expired - Fee Related
- 2001-04-11 WO PCT/DK2001/000267 patent/WO2001076555A2/en active IP Right Grant
- 2001-04-11 JP JP2001574159A patent/JP2003530362A/ja not_active Withdrawn
- 2001-04-11 DK DK01921262T patent/DK1272161T3/da active
- 2001-04-11 US US10/239,515 patent/US7368254B2/en not_active Expired - Fee Related
- 2001-04-11 US US10/239,527 patent/US7166297B2/en not_active Expired - Fee Related
-
2006
- 2006-11-16 CY CY20061101675T patent/CY1105792T1/el unknown
- 2006-12-12 US US11/609,773 patent/US20070134153A1/en not_active Abandoned
-
2007
- 2007-04-16 CY CY20071100522T patent/CY1106462T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1106462T1 (el) | Συστηματα απελευθερωσης φαρμακου με βαση λιπιδιο για τοπικη εφαρμογη | |
CY1119252T1 (el) | Νεα παραγωγα 1-βενζυλο-3 -υδροξυμεθυλινδαζολης και χρηση αυτων στη θεραπεια νοσων που βασιζονται στην εκφραση των cx3cr1 και ρ40 | |
PA8570901A1 (es) | Derivados de acil-4-carboxifenilurea, procedimientos para su preparacion y su uso | |
CY1116075T1 (el) | Νεες συνθεσεις λιποσωματων | |
CY1110954T1 (el) | Ημιστερεες βλεννοκολλωδεις φαρμακοτεχνικες μορφες | |
CY1110271T1 (el) | Υδατικες παρατεταμενης-απελευθερωσης φαρμακοτεχνικες μορφες πρωτεϊνων | |
BR9908757A (pt) | Derivados de 3-hidróxi-4-aril-5-oxopirazolina herbicidamente ativos | |
CY1111541T1 (el) | Αγωνιστες β-2 αδρενοϋποδοχεα για την αγωγη παθησεων συνδετικου ιστου του δερματος | |
CY1105060T1 (el) | Νεες σουλφαμιδες και η χρηση τους σαν ανταγωνιστικων ληπτων ενδοθηλινης | |
CU23208A3 (es) | Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea | |
TR199800436A2 (xx) | Primidin t�revlerinin kanserin �nlenmesi i�in kullan�lmas�. | |
ES2192301T3 (es) | Derivados de resorcinol. | |
HN2002000208A (es) | 1-ALQUIL O 1 - CICLOALQUIL-TRIAZOLO [4.3 - a] QUINAZOLIN -5-ONAS COMO INHIBIDORES DE FOSFODIESTERASAS | |
CY1112793T1 (el) | Αντισωματα που συνδεονται ανοσοειδικως προς blys | |
DE60106954D1 (de) | Resorcin-derivate | |
CY1105942T1 (el) | Sgk3 ως διαγνωστικος και θepαπευτικος στοχος | |
CY1116544T1 (el) | Χρηση της λυσοσωμικης οξινης λιπασης για την αγωγη της ανεπαρκειας λυσοσωμικης οξινης λιπασης σε ασθενεις | |
AR035284A1 (es) | Formulaciones en combinacion de derivados de propanol-amina sustituidos con arilo, junto con otras sustancias activas y su utilizacion | |
HN2000000075A (es) | Profarmacos mutuos amlodipino y atorvastatina | |
AR021843A1 (es) | Derivados de propanolamina sustituidos con heterociclos, procedimiento para su preparacion, y su utilizacion. | |
BR0009211A (pt) | Derivados de resorcinol | |
BR0013014A (pt) | Derivados de 6-aza uracila inibindo interleucina-5 | |
TR200103249T2 (tr) | Migrenin tedavisi ve önlenmesinde valproik asit analoğu kullanımı. | |
UY27419A1 (es) | Formulaciones en combinación de derivados de 1,4-benzotiepina-1,1-dioxido con otras sustancias activas, y su utilización. | |
BR0009194A (pt) | Composição do resorcinol |